As the world continues to adapt to the global public health situation, Treg Therapy developers are still actively seeking external partners that can provide solutions to the challenges they are facing when manufacturing, engineering and understanding these therapies.
Whilst Treg directed therapies have shown great preclinical potential, and there are now more than 50 active and completed clinical trials, they still have challenges to overcome.
Tregs need to be effectively expanded ex vivo to achieve sufficient numbers for clinical use. Many challenges remain in this manufacturing process including purification, expansion, dosage and functional standards of Treg cells. Furthermore, as more and more engineered Treg products are developed, such as CAR-Tregs, challenges will appear in genetic engineering and large-scale manufacturing of CAR-Tregs.
The digital 3rd Treg Directed Therapy Summit offers a unique opportunity to collaborate with key industry decision-makers in the space.
We’ll work with you to build a bespoke partnership package focused on making valuable connections & generating actionable leads to ensure you meet your 2021 commercial objectives in this new digital reality.
Contact us today to learn how we can help you achieve your business goals faster, more effectively, and more cost-efficiently.
Maximize the 2:1 balance of live content and targeted online networking to generate leads and build new relationships with senior-level decision-makers from leading pharma and biotech companies
Secure a branding or speaking opportunity to demonstrate thought leadership, drive brand exposure and differentiate yourself from competitors.
Secure a virtual exhibition booth to showcase your expertise and educate the industry on how you can support and streamline their efforts.
Embrace the tech to meet your 2020 commercial objectives and educate key decision-makers on how your expertise can help the Treg community achieve their full potential and reach patients in need.